Skip to main content
Skip to content
Case File
kaggle-ho-024891House Oversight

Regulatory overview of CBD under the 2018 Farm Bill and FDA authority

Regulatory overview of CBD under the 2018 Farm Bill and FDA authority The passage outlines publicly known regulatory changes and FDA statements about CBD. It contains no new allegations, financial flows, or links to powerful individuals beyond the mention of FDA Commissioner Scott Gottlieb, offering minimal investigative value. Key insights: 2018 Farm Bill declassifies industrial hemp and shifts regulatory authority from DEA to USDA.; FDA retains authority over CBD products intended for human consumption.; FDA Commissioner Scott Gottlieb issued statements reaffirming regulatory oversight and warning against unapproved health claims.

Date
Unknown
Source
House Oversight
Reference
kaggle-ho-024891
Pages
1
Persons
0
Integrity
No Hash Available

Summary

Regulatory overview of CBD under the 2018 Farm Bill and FDA authority The passage outlines publicly known regulatory changes and FDA statements about CBD. It contains no new allegations, financial flows, or links to powerful individuals beyond the mention of FDA Commissioner Scott Gottlieb, offering minimal investigative value. Key insights: 2018 Farm Bill declassifies industrial hemp and shifts regulatory authority from DEA to USDA.; FDA retains authority over CBD products intended for human consumption.; FDA Commissioner Scott Gottlieb issued statements reaffirming regulatory oversight and warning against unapproved health claims.

Tags

kagglehouse-oversightcbdregulationfdafarm-billhemp

Forum Discussions

This document was digitized, indexed, and cross-referenced with 1,500+ persons in the Epstein files. 100% free, ad-free, and independent.

Annotations powered by Hypothesis. Select any text on this page to annotate or highlight it.